Physician profile
Sara Huser
NPI 1316359664
$8,722.10
in general payments reported to CMS, 2019-2025
38 companies · $69.69 in 2025
The $69.69 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.39 · 2020: $287 · 2021: $1,250 · 2022: $1,558 · 2023: $3,488 · 2024: $2,008 · 2025: $69.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,557 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,557.26 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,497.35 | 2020-2024 | |
| Abbvie INC. | $1,250.49 | 2021-2024 | |
| Biogen, INC. | $700.93 | 2020-2024 | Vumerity, Tysabri, Tysabri |
| Ucb, INC. | $549.50 | 2019-2024 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $519.04 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $458.66 | 2020-2024 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $415.95 | 2019-2024 | Nuplazid |
| Lundbeck LLC | $353.72 | 2021-2024 | Vyepti, Rexulti |
| Argenx US, INC. | $314.28 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $283.34 | 2021-2024 | Emgality, Amyvid, Reyvow |
| Amgen INC. | $278.16 | 2021-2023 | Aimovig |
| Genentech USA, INC. | $249.57 | 2022-2024 | Ocrevus, Evrysdi |
| Eisai INC. | $190.79 | 2023-2024 | |
| Neurelis, INC. | $183.51 | 2021-2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $151.08 | 2023-2024 | Austedo Xr, Ajovy |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Huser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.